Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.

Çağdaş Erdoğan,Bayram Yeşil,Ferhat Bacaksız,Derya Arı,Volkan Gökbulut,Mahmut Yüksel,Yasemin Özderin Özin,Ertuğrul Kayaçetin

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology（2022）

引用 0|浏览0

暂无评分

摘要

Vedolizumab therapy is effective in both induction and maintenance of remission in inflammatory bowel disease patients who are resistant to anti-tumor necrosis factor or who can not receive anti-tumor necrosis factor therapy due to side effects. No signifi- cant side effect was observed in the patients during follow-up.

查看译文

关键词

Crohn's disease, inflammatory bowel disease, ulcerative colitis, vedolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要